Exane Derivatives’s Aurinia Pharmaceuticals AUPH Stock Holding History

Exane Derivatives’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$87.2K	Hold	8,683	–	–	0.05%	274
2022 Q1	$107K	Buy	8,683 +1,182	+16%	+$18.3K	0.03%	464
2021 Q4	$172K	Sell	7,501 -6,828	-48%	-$162K	0.04%	362
2021 Q3	$317K	Buy	14,329 +1,185	+9%	+$18.8K	0.08%	274
2021 Q2	$157K	Buy	13,144 +4,404	+50%	+$56.1K	0.04%	462
2021 Q1	$113K	Sell	8,740 -1,388	-14%	-$20.1K	0.03%	404
2020 Q4	$140K	Buy	10,128 +5,028	+99%	+$73.2K	0.04%	348
2020 Q3	$75.1K	Buy	5,100 +1,700	+50%	+$24.6K	0.02%	340
2020 Q2	$55.2K	Buy	+3,400	New	+$54.4K	0.01%	346

Other funds holding AUPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Exane Derivatives's AUPH Position: Q2 2022 in Review

Exane Derivatives held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2022 at 8,683 shares worth $87.2K. The position accounts for 0.05% of the portfolio, ranked #274.

Exane Derivatives first reported a position in AUPH in Q2 2020 and has held it in 9 quarters since. The position peaked at $317K in Q3 2021. 199 funds tracked by Wall St. Rank hold AUPH as of Q2 2022.

Exane Derivatives held 8,683 shares of Aurinia Pharmaceuticals worth $87.2K as of Q2 2022.
Exane Derivatives left its Aurinia Pharmaceuticals share count unchanged in Q2 2022.
Aurinia Pharmaceuticals made up 0.05% of Exane Derivatives's portfolio in Q2 2022, its #274 holding.
Exane Derivatives first reported a position in Aurinia Pharmaceuticals in Q2 2020 and has held it in 9 quarters since.
Exane Derivatives's Aurinia Pharmaceuticals position peaked at $317K in Q3 2021.
199 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.